REG - AOTI, Inc. - Result of AGM

AotiAnnouncement

25/06/2025 13:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nRSY4109Oa&default-theme=true

RNS Number : 4109O  AOTI, Inc.  25 June 2025

25 June 2025

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Result of Annual General Meeting

 

The Annual General Meeting of AOTI, INC. was held at Temple Chambers, 3 - 7
Temple Avenue, EC4Y 0DT on 25 June 2025 at 10:00 a.m.

 

All 10 resolutions put to members were passed on a poll. Resolutions 1-9 were
passed as ordinary resolutions and resolution 10 was passed as a special
resolution.

 

The number of votes cast for and against each of the resolutions proposed, and
the number of votes withheld were as follows:

 

 Resolution                                                                      Votes for   %       Votes against  %     Votes withheld
 Resolution 1 (Ordinary)                                                         73,445,182  99.49   378,787        0.51  1,688,157

 To receive and adopt the statement of accounts for the year ended 31 December
 2024 together with the reports of the Directors and the auditors thereon.
 Resolution 2 (Ordinary)                                                         74,873,339  99.15   638,787        0.85  0

 To appoint Douglas Le Fort as a director of the Company
 Resolution 3 (Ordinary)                                                         75,512,126  100.00  0              0.00  0

 To appoint Michael Griffiths as a director of the Company
 Resolution 4 (Ordinary)                                                         75,512,126  100.00  0              0.00  0

 To appoint Anthony Bourne as a director of the Company
 Resolution 5 (Ordinary)                                                         75,133,339  100.00  0              0.00  378,787

 To appoint Richard Cotton as a director of the Company
 Resolution 6 (Ordinary)                                                         75,512,126  100.00  0              0.00  0

 To appoint Ceri Morgan as a director of the Company
 Resolution 7 (Ordinary)                                                         75,512,126  100.00  0              0.00  0

 To appoint Jayesh Pankhania as a director of the Company
 Resolution 8 (Ordinary)                                                         74,664,682  98.88   847,444        1.12  0

 To re-appoint Grant Thornton (Ireland) as auditor of the Company
 Resolution 9 (Ordinary)                                                         67,956,008  90.33   7,270,813      9.67  285,305

 To authorise the Directors to determine the fees payable to the auditor
 Resolution 10 (Special)                                                         66,599,498  99.56   295,455        0.44  8,617,173

 To disapply pre-emption rights generally

 

As previously disclosed in the Admission Document in June 2024 Anthony Moffat
did not seek re-election at the Annual General Meeting and has stepped down
from his role as a Director of the Company. Anthony Moffat will continue in
his current role as COO of the Company.

 

As at 25 June 2025, there were 106,359,163 Common shares in issue.
Shareholders are entitled to one vote per share. Votes withheld are not votes
in law and so have not been included in the calculation of the proportion of
votes for and against a resolution.

 

The full text of each resolution is available in the Notice of Annual General
Meeting, published on our website.

 

ENDS

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer   +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer     ir@aotinc.net (mailto:ir@aotinc.net)
 Peel Hunt LLP (Nominated Adviser and Broker)

 Dr. Christopher Golden, James Steel           +44 (0)20 7418 8900
 FTI Consulting (Financial PR & IR)

 Ben Atwell, Simon Conway,                     +44 (0)20 3727 1000

 Natalie Garland-Collins, Alex Davis           AOTI@fticonsulting.com (mailto:AOTI@fticonsulting.com)

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalisations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA),
Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical
Products Administration, Australia (TGA) and in Saudi Arabia. Also
see www.aotinc.net (http://www.aotinc.net/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEEFEIEISEEM